# Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma

> **NCT00023816** · PHASE1 · UNKNOWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Lymphoma
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** carbendazim

## Key facts

- **NCT ID:** NCT00023816
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00023816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00023816, "Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00023816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*